drugset / Trial / NCT00251719

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

NCT00251719 ↗

Phase 3 Completed 2054 enrolled Takeda
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a study to assess the efficacy and safety of 8 weeks of treatment with Dexlansoprazole modified release (MR)(60 mg daily and 90 mg daily) compared to Lansoprazole (30 mg daily) in healing subjects with endoscopically proven erosive esophagitis.

Timeline

Start
2005-12
Primary completion
2007-01
Completion
2007-01

Outcome

Met primary endpoint

paper Dexlansoprazole MR achieved non-inferiority to lansoprazole, allowing testing for superiority. PMID 19183157 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexlansoprazole Other / unclassified 60 mg Oral
Subject Dexlansoprazole Other / unclassified 90 mg Oral
Comparator Lansoprazole Other / unclassified 30 mg Oral